PCN199 THE IMPACT OF PCODR COMING UNDER THE REMIT OF CADTH: 3 YEAR UPDATE

Abstract

The pan-Canadian Oncology Drug Review (pCODR) was established in 2010 to bring consistent oncology drug assessments across Canadian provinces/territories. In April 2014, pCODR was transferred to the Canadian Agency for Drugs and Technologies in Health (CADTH). This transfer comprised two phases. In phase 1, pCODR staff, processes, funding, and expertise remained intact as a program but under the government of CADTH. In Phase 2, beginning April 2015, better alignment of pCODR and CADTH evaluation criteria and review processes were explored. This research aims to see what effect the CADTH transfer has had on the number of appraisals conducted by pCODR and their recommendation rates. All publically available pCODR reports were extracted up to 31st December and the drug, indication, date and outcome were extracted. Statistical comparisons were made using Student’s t-test. 119 appraisals have been conducted by pCODR, reflecting an average of 19.0/year (10 in 2012, 18 in 2013, 9 in 2014, 24 in 2015, 19 in 2016, 17 in 2017 and 22 in 2018). The rate of appraisals was similar pre-CADTH transfer (14.2/year [32 from January 2012 to March 2014]) versus post-CADTH transfer (13.7/year [56 from April 2014 to November 2017]). 78% of pCODR outcomes were positive recommendations (defined as full recommendations [11%] or restricted/conditional recommendations [67%]) with 23% not recommended). Annually, positive recommendation rates were 70% in 2012, 89% in 2013, 78% in 2014, 79% in 2015, 74% in 2016, 76% in 2017 and 78% in 2018. There were no significant differences in recommendation rates since pCODR was transferred to CADTH irrespective if the Phase 1 or Phase 2 cut-off dates were used (p=0.793 and 0.900, respectively). The number of appraisals and likelihood of a positive recommendation for oncology drugs has not been affected by the pCODR transfer to CADTH.